Cutler Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Cutler Group’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,000	Closed	-$2K	–	5660
2017 Q4	$2K	Buy	+3,000	New	+$10.9K	﹤0.01%	4299
2017 Q3	–	Sell	-3,000	Closed	-$1K	–	7137
2017 Q2	$1K	Buy	+3,000	New	+$12.1K	﹤0.01%	6161
2016 Q4	–	Sell	-900	Closed	-$1K	–	7715
2016 Q3	$1K	Hold	900	–	–	﹤0.01%	6447
2016 Q2	$1K	Sell	900 -6,600	-88%	-$56.6K	﹤0.01%	6418
2016 Q1	$4K	Sell	7,500 -20,800	-73%	-$152K	﹤0.01%	5151
2015 Q4	$73K	Buy	+28,300	New	+$257K	﹤0.01%	2073

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cutler Group's ACHN Position: Q1 2018 in Review

Cutler Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 354 shares — an estimated $1K sold.

Cutler Group first reported a position in ACHN in Q4 2015 and held it in 6 quarters. The position peaked at $259K in Q4 2015. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

Cutler Group reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Cutler Group sold 354 Achillion Pharmaceuticals shares in Q1 2018, an estimated $1K.
Cutler Group first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Cutler Group's Achillion Pharmaceuticals position peaked at $259K in Q4 2015.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Cutler Group's 13F filing for Q1 2018, filed 11 May 2018.